Reported 12 months ago
A Harvard study found that weight-loss drugs Ozempic and Wegovy, including GLP-1 drugs from Novo Nordisk (NVO) and Eli Lilly (LLY), may be associated with rare cases of vision loss. The study is observational and focused on semaglutide, emphasizing that the findings are not broadly applicable to all GLP-1 drugs. The FDA and EU previously found no links to suicide ideation in these drugs. Researchers emphasize the need for further studies on this potential association.
Source: YAHOO